Phase 1–2 study | Liso-cel shows effectiveness against resistant CLL/SLL post BTK inhibitor, venetoclax treatment
20 Jul, 2023 | 10:58h | UTCLisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study – The Lancet (link to abstract – $ for full-text)
News Release: Immunotherapy Improves Remission for Relapsed, Refractory Leukemia – Northwestern Medicine